Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China flag China · Delayed Price · Currency is CNY
11.33
-0.21 (-1.82%)
Nov 13, 2026, 1:55 PM CST

SHE:300233 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
157.1544.19196.78174.71273.37107.98
Depreciation & Amortization
321.52321.52319.26308.17255.77224.03
Other Amortization
3.163.163.513.493.019.46
Loss (Gain) From Sale of Assets
-2.95-2.95-1.452.16-1.53-1.02
Asset Writedown & Restructuring Costs
23.8623.8614.532.4921.3239.07
Loss (Gain) From Sale of Investments
-2.79-2.791.67-0.598.68-12.5
Provision & Write-off of Bad Debts
0.390.39-2.492.77-0.08-4.52
Other Operating Activities
11.5838.8342.4888.0350.9178.41
Change in Accounts Receivable
58.1758.17-28.11-124.9-314.2-89.1
Change in Inventory
101.37101.37-115.5932.08-202.78-133.37
Change in Accounts Payable
-263.48-263.48-137.11213.55127.52194.72
Change in Other Net Operating Assets
----16.4621.35-
Operating Cash Flow
405.35319.64296.59664.08255.63437.19
Operating Cash Flow Growth
45.11%7.77%-55.34%159.78%-41.53%-19.95%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-90.49-100.88-142.61-342.9-373.67-376.14
Sale of Property, Plant & Equipment
57.2723.7962.2924.866.485.67
Divestitures
-----0.96-
Investment in Securities
-71.34-68.34-4103.9129.1
Other Investing Activities
-4.19-10.520.01-1.956.429.84
Investing Cash Flow
-108.74-155.96-84.32-309.99-357.82-231.54

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-137.98239348.37475.97383.7
Long-Term Debt Repaid
--274.17-283.38-449.03-418.99-390.7
Lease Payments
-2.14-2.14-2.6-2.82-4.15-5.58
Net Debt Issued (Repaid)
-164.21-136.19-44.38-100.6656.98-7
Issuance of Common Stock
----56.94-
Repurchase of Common Stock
---55.01---80.01
Common Dividends Paid
-64.72-162.51-131.67-83.52-104.78-105.19
Other Financing Activities
0.13--12.71-59.13-5.310.54
Financing Cash Flow
-228.79-298.7-243.77-243.313.83-191.66

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-2.861.845.963.474.3-4.97
Net Cash Flow
64.94-133.17-25.54114.24-94.079.01

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
314.86218.76153.97321.18-118.0461.04
Free Cash Flow Growth
80.49%42.08%-52.06%---77.70%
Free Cash Flow Margin
11.11%7.99%4.56%9.08%-3.37%1.94%
Free Cash Flow Per Share
0.880.590.410.83-0.310.16
Levered Free Cash Flow
295278.7716.57251.22115.339.67
Unlevered Free Cash Flow
299.94285.5328.12266.8132.0926.57
Free Cash Flow After Leases
312.72216.62151.37318.36-122.1955.46

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
203.38195.64172.91155.47114.1151.12
Change in Working Capital
-106.57-106.57-277.6982.85-355.82-3.72